Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. ashpublications.org › blood › articleAcute Myeloid Leukemia Driven IL-3 Dependent Upregulation of ...

    2 de nov. de 2023 · The BH3 mimetic venetoclax, in combination with low dose cytarabine, decitabine or azacitidine has shown clinical efficacy in newly diagnosed acute myeloid leukemia (AML) (1, 2).

  2. biomarkerres.biomedcentral.com › articles › 10Venetoclax and Daratumumab combination treatment demonstrates ...

    13 de may. de 2021 · Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo.

    • Jayna J Mistry, Jayna J Mistry, Charlotte Hellmich, Charlotte Hellmich, Amelia Lambert, Jamie A Moor...
    • 2021

  3. www.ncbi.nlm.nih.gov › pmc › articlesVenetoclax and Daratumumab combination treatment demonstrates ...

    13 de may. de 2021 · Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.

    • Jayna J Mistry, Jayna J Mistry, Charlotte Hellmich, Charlotte Hellmich, Amelia Lambert, Jamie A Moor...
    • 10.1186/s40364-021-00291-y
    • 2021
    • Biomark Res. 2021; 9: 35.

  4. ncbi.nlm.nih.gov › pmc › articlesP423: ACUTE MYELOID LEUKEMIA REPROGRAMS LIPID METABOLISM BY ...

    8 de ago. de 2023 · P423: ACUTE MYELOID LEUKEMIA REPROGRAMS LIPID METABOLISM BY DOWNREGULATING CD36 EXPRESSION IN HEPATOCYTES. Rebecca Maynard, 1 Katherine Hampton, 1 Charlotte Hellmich, 1 Martha Ehikioya, 1 Dominic Fowler-Shorten, 1 Kristian Bowles, 1 and Stuart Rushworth 1.

  5. Imágenes

    • Charlotte Hellmich Wife of German general and minister of defence ...
    • NTV-Turnerinnen erstmals im neuen Sportzentrum - Velbert
    • Charlotte Hellmich (@c_hellmich) / Twitter
    • Charlotte Hellmich (@c_hellmich) / Twitter
    • British Guardian: The Downfall of Field Marshal Werner von Blomberg
    • News/Events | Norwich Cancer Research Network

    Ver todo

  6. ashpublications.org › blood › articleInvestigating the Dual Targeting of BCL-2 and CD38 in Models ...

    5 de nov. de 2020 · Current AML treatment often fails to achieve complete remission and relapse is common, highlighting the need for more targeted treatments. Overexpression of BCL2 is a hallmark of AML progression and is often associated with a poor response to cytotoxic treatment.

    • Jayna J Mistry, Charlotte Hellmich, Amelia Lambert, Jamie A Moore, Aisha Jibril, Angela Collins, Fed...
    • 2020

  7. pubmed.ncbi.nlm.nih.gov › 38186347Acute myeloid leukemia driven IL-3-dependent upregulation of ...

    Acute myeloid leukemia driven IL-3-dependent upregulation of BCL2 in non-malignant hematopoietic stem and progenitor cells increases venetoclax-induced cytopenias.

  8. www.sciencedirect.com › science › articleAcute Myeloid Leukemia Driven IL-3 Dependent Upregulation of ...

    2 de nov. de 2023 · The BH3 mimetic venetoclax, in combination with low dose cytarabine, decitabine or azacitidine has shown clinical efficacy in newly diagnosed acute myeloid leukemia (AML) (1, 2). This has been a significant advance, particularly in the treatment of older AML patients, and those who are ineligible for intensive chemotherapy, who ...